HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
The Week

Spurned by FDA, Passage Bio finds exit through merger with Remix

Passage Bio, the Philadelphia-based gene therapy outfit that launched a strategic review earlier this year after tough feedback from the FDA, has found an exit in an all-stock reverse merger with RNA specialist Remix Therapeutics.

By FierceBiotech · Jun 25, 2026 · via FierceBiotech
Spurned by FDA, Passage Bio finds exit through merger with Remix

Image: FierceBiotech

This is an aggregated industry headline. Read the full story at FierceBiotech →

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.

Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
AstraZeneca spells out a community cancer screening strategy with the YMCA
AstraZeneca has partnered with YMCA of the USA to increase awareness of cancer screening and early detection.…
Jun 25, 2026
Gilead’s Trodelvy Wins Broad Front-Line TNBC Nod, Escalating TROP2 ADC Competition
The WeekBriefing
Gilead’s Trodelvy Wins Broad Front-Line TNBC Nod, Escalating TROP2 ADC Competition
The FDA approved Trodelvy for first-line triple-negative breast cancer regardless of PD-L1 status, days after …
Jun 25, 2026
STAT+: Facing a brutal run, battered vaccine makers still see cause for hope
The WeekSTAT News ↗
STAT+: Facing a brutal run, battered vaccine makers still see cause for hope
It's an unusual time to be in the vaccine business. But in the view of those gathered at the BIO conference th…
Jun 25, 2026